This study evaluated the in vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. The drug inhibited all tested members of the family Enterobacteriaceae at Յ0.5 g/ml and all tested Pseudomonas aeruginosa, Burkholderia (Pseudomonas) cepacia, and Xanthomonas maltophilia strains at Յ2 g/ml. All but two strains of gram-positive bacteria were inhibited by Յ1 g of the new drug per ml, including isolates highly resistant to ciprofloxacin.
The compound A-86719.1 ( Fig. 1 ) is a novel 2-pyridone antimicrobial agent which, like the fluoroquinolones, inhibits bacterial DNA gyrase. The DNA gyrase cleavage activities (the concentrations of drug required to yield 50% DNA cleavage) of A-86719.1 and norfloxacin for Escherichia coli gyrase are 0.03 and 0.4 g/ml, respectively (2) . However, because the novel basic ring structure of the molecule is different from that of the quinolines or naphthyridines, it may bind differently from existing quinolones at the enzymatic site. Hence, the compound is potentially active against fluoroquinolone-resistant bacteria (4) . This study was designed to examine the in vitro antimicrobial spectrum of the new compound against a wide selection of bacteria, including strains resistant to ciprofloxacin.
MATERIALS AND METHODS
Most organisms used in the study were clinical isolates recovered from 1990 to 1993 at the Deaconess Hospital or the Massachusetts General Hospital, Boston, Mass. Occasional isolates with specific resistance traits and many of the grampositive organisms had been referred to our laboratory from other sources as well. Bacteria were stored at Ϫ70ЊC until used.
Antimicrobial susceptibility was determined by an agar dilution technique as recommended by the National Committee for Clinical Laboratory Standards (7). Inocula were prepared from overnight cultures and applied to the surfaces of plates with a multiprong replicator yielding final inocula of approximately 10 4 CFU per spot. For aerobic and facultative organisms, Mueller-Hinton II agar (BBL Microbiology Systems, Cockeysville, Md.) was used. The concentration of agar was increased to 4% when Proteus mirabilis and Proteus vulgaris were tested. For streptococci and diphtheroids, 5% sheep blood was added to the agar. Bacteroides fragilis was tested on Oxoid Wilkins-Chalgren agar (Unipath Ltd., Basingstoke, England) at an inoculum of 10 4 CFU per spot. Anaerobic atmospheres were generated with the GasPak Plus System (BBL). Other plates were incubated in room air or with 5% CO 2 supplementation (Streptococcus pneumoniae, Leuconostoc spp., Lactobacillus spp., Pediococcus spp., Erysipelothrix spp., and diphtheroids). Pneumococci were also tested by the broth microdilution method in cation-adjusted Mueller-Hinton broth with 5% lysed horse blood (7) .
A-86719.1 was provided by Abbott Laboratories, Abbott Park, Ill. Clinafloxacin was a generous gift of Parke-Davis Pharmaceutical Research, Ann Arbor, Mich. Ciprofloxacin was provided by Miles Pharmaceuticals, West Haven, Conn.
RESULTS AND DISCUSSION
The in vitro activity of A-86719.1 as compared with those of clinafloxacin and ciprofloxacin is shown in Table 1 . All three agents were highly active against the members of the family Enterobacteriaceae tested. The 2-pyridone inhibited all 183 tested members of the family Enterobacteriaceae at concentrations of 0.5 g/ml or less. Only one ciprofloxacin-resistant strain of Enterobacter cloacae was encountered (MIC ϭ 4 g/ ml), and this was substantially more susceptible to the new compound (MIC ϭ 0.25 g/ml). A-86719.1 and clinafloxacin were the most active of the three agents against Pseudomonas aeruginosa and Burkholderia (Pseudomonas) cepacia as well as Xanthomonas maltophilia, Campylobacter jejuni, and Acinetobacter spp. Both A-86719.1 and clinafloxacin were substantially more active than ciprofloxacin against strains of B. fragilis.
All staphylococci were inhibited by the new agent at concentrations of 1 g/ml or less, including strains resistant to ciprofloxacin (MICs in excess of 128 g/ml). Various streptococci, including penicillin-susceptible and -resistant strains of S. pneumoniae and viridans group streptococci, were inhibited by A-86719.1 at concentrations of 0.12 g/ml or less. Sixty isolates of S. pneumoniae collected in 1993 and 1994 were also tested by the broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards (7) which confirmed the high activities of the 2-pyridone and clinafloxacin, with MICS even lower than those determined by agar dilution. MICs at which 90% of the strains tested were inhibited (MIC 90 s) (MIC ranges) were as follows: A-86719.1, Յ0.015 g/ml (Յ0.015 to 0.03 g/ml); clinafloxacin, 0.06 g/ml (Յ0.015 to 0.12 g/ml); and ciprofloxacin, 2 g/ml (0.25 to Ͼ16 g/ml). Activity of this magnitude against pneumococci could prove very important, given the increasing antimicrobial resistance noted in this species. All of the other gram-positive organisms tested were inhibited by the new compound at Յ1 g/ml, including multidrug-resistant strains of enterococci, except for two isolates of Enterococcus faecium which were also highly resistant to ciprofloxacin. Against the enterococci, the novel compound was generally twofold more active than clinafloxacin on the basis of MIC 90 s. Because of the high activity of all of the compounds tested, it seems unlikely that A-86719.1 would provide a significant advantage over ciprofloxacin against members of the Enterobacteriaceae; however, other species of gram-negative organisms tested were substantially more susceptible to the new agent than to ciprofloxacin. Many strains of X. maltophilia are currently resistant to a broad array of available antimicrobial agents, including ciprofloxacin (5); all of these were inhibited by the new compound at 2 g/ml or less. In addition, the weak activity of currently available fluoroquinolones against anaerobic gram-negative bacteria has been an important deficiency in the spectrum of these agents (3). The new compound was the most potent of the three agents that we tested here against B. fragilis, with an MIC 90 that was 64-fold lower than that of ciprofloxacin even at the low inoculum tested.
Greater in vitro potency of A-86719.1 as compared with that of ciprofloxacin was noted against all of the gram-positive organisms tested. In almost all cases, organisms, including strains of Enterococcus faecalis and E. faecium, were inhibited by Յ1 g of the new compound per ml. Multiply resistant enterococci have recently appeared in several centers in the United States and Europe and have posed an important challenge to antimicrobial therapy (1, 6, 8) . New agents with activity against these organisms are sorely lacking, and in this regard, the new compound appears quite promising. Nevertheless, the detection of enterococci for which MICs of the new compound were as high as 8 g/ml suggests the existence of populations of resistant organisms. Hence, further resistance to this novel class of agents may develop over time.
This study demonstrates the wide spectrum of activity of this novel compound which might be of value in the treatment of polymicrobial infections or for empirical therapy and suggests as well its potential utility against multidrug-resistant organisms, including methicillin-resistant staphylococci and vancomycin-resistant enterococci. Clinical studies would be necessary to establish the ultimate usefulness of this compound.
